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Ah = Aryl hydrocarbon 
ALK5 = Activin receptor-like kinase 5 
AMPK = adenosine monophosphate (AMP) activated kinase 
Apc/APC= Adenomatous polyposis coli 
ARK5 = AMPK related kinase 5 
ATM = Ataxia Telangiectasia mutated 
ATG13 = Autophagy related 13 homolog 
ATP = Adenosine triphosphate 
BRSK = Brain-specific serine/threonine kinase 
CAB39 = calcium binding protein 39 
CaMKK = calcium/calmodulin dependent protein kinase kinase 
Cdc37= Cell division cycle 37 
CHIP = carboxyl terminus of Hsc70-interacting protein 
COX-2 = Cyclooxygenase-2 
CRM = Chromosome region maintenance  
CT = Computer assisted Tomography 
C-TAK = Cdc25 C-associated kinase 
DCC = Deleted in colorectal cancer 
DMBA = Dimethylbenzanthracene 
Dn= dominant negative 
4E-BP= Eukaryotic translation initiation factor 4E-binding protein 
EMT= epithelial-to-mesenchymal transition 
ERK= Extracellular-signal-regulated kinases 
ERT= Estrogen receptor Tamoxifen inducible 
FAP= Familial Adomatous Polyposis 
FIP200= focal adhesion kinase family interacting protein of 200 kD 
FH= Fumarate hydratase protein  
GSK= Glycogen synthase kinase 
HDAC4= Histone deacetylase 4 
Het= heterozygous 
HIF= Hypoxia inducible factor 
HLRCC = Hereditary leiomyomatosis and renal cell cancer 
Hmz= homozygous 
HPGL= hereditary paragangliomatosis with phaeochromocytomas 
Hsp= heat shock protein  
i.p.= intraperitoneal 
IP = immunoprecipitate 
KD = kinase dead 
KLK10= kallikrein-related peptidase 10 
LKB1= Liver Kinase B1 
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ABSTRACT 
The Peutz-Jeghers Syndrome is a rare cancer predisposition condition, caused by 
mutations inactivating the LKB1 tumor suppressor kinase. This study aimed to 
further the understanding of this disease, provide potential means of treatment to 
Peutz-Jeghers patients, and to add to our understanding of cancer formation in 
general. These aims were pursued through exploring the molecular functions of the 
LKB1 kinase, studying the tumor formation upon loss of LKB1 function, and 
through intervening with this tumor formation process. The study was mainly 
performed in the Lkb1 knockout mouse or derived tissues and cells, but partly also 
with Peutz-Jeghers patients and patient materials.  
 
We found that the LKB1 kinase phosphorylates and thereby activates 13 kinases in 
the AMP-activated kinase family, any of which could putatively relay the tumor 
suppressor functions of LKB1. We also found that Cyclooxygenase-2 participates 
in tumorigenesis in Peutz-Jeghers syndrome by promoting the growth of gastric 
polyps, and that inhibitor treatment suppresses the polyp formation. We also 
observed that these Peutz-Jeghers polyps are less differentiated than previously 
thought, and that signs of poor differentiation can be seen in the gastric epithelium 
already prior to polyp formation. In addition, we found that the polyp formation 
process is likely to be enhanced by other genes in addition to LKB1 and 
Cycloxygenase-2, as alkylating mutagenesis increased polyp formation 
independently of the activity of the latter. 
 
Taken together, these results point to a wide array of molecules and processes 
interplaying in Peutz-Jeghers tumorigenesis beyond the LKB1 kinase. Both straight 
molecular targets of LKB1 activity, indirect mediators of LKB1-regulated 
tumorigenesis, and cooperating processes have been identified. One may expect 
that these findings will be of use for future studies both characterizing the Peutz-
Jeghers syndrome and targeting treatments for this and related tumor diseases. 
Review of the Literature 
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INTRODUCTION 
Cancer is a worldwide concern, affecting more than every third person in developed 
countries (www.cancer.org and info.cancerresearchuk.org). It is caused by mutations 
affecting the growth of cells and how they interact with their surroundings. Such 
mutations usually occur by environmental impact, although some mutations predisposing 
for cancer are inheritable and passed on in families as disease entities. The Peutz-Jeghers 
syndrome (PJS) discussed below in this study is an example of such an inheritable 
condition, although in addition to being inherited (as an autosomal dominant disease) it 
may also occur sporadically by de novo mutation.  
 
The frequency estimates for PJS lie somewhere between 1:29 000 (Mallory and Stough 
1987) to less than 1:200 000 (Eng et al. 2001) rendering it very rare in comparison to the 
worldwide cancer burden. On the other hand, being a genetically characterized disease, 
dependent on a single gene, Liver Kinase B1 (LKB1), PJS has offered a route to model 
and explore cancer from the perspective of this particular tumor suppressor. Study tools 
and lessons learnt from the experimental models of PJS have also been used in the study 
of cancer beyond the Peutz-Jeghers syndrome (as discussed further below). 
 
 
REVIEW OF THE LITERATURE 
1 The Peutz-Jeghers syndrome 
The Peutz-Jeghers Syndrome (PJS) presents as triad of mucocutaneous pigmentations, 
polyposis and increased cancer risk (Peutz 1921; Jeghers et al. 1949). The malignant 
tumors are mainly carcinomas and most commonly arise in the gastrointestinal tract, 
where the relative risks of developing cancer has been estimated to be 84-fold for colon, 
213-fold for gastric, and 520-fold for small intestinal cancer (Giardiello et al. 2000).  
 
A number of other cancer types, like pancreatic, breast and lung cancers also occur with 
a much higher frequency in PJS than in the normal population(Hearle et al. 2006a; van 
Lier et al. 2011), and some very unusual cancer types occur, including adenoma 
malignum of the cervix, Sertoli cell tumour of the ovary and feminizing Sertoli cell 
tumor of the testes. Also, the ovarian sex-cord tumors with annular tubules (SCTAT), 
which only rarely have been observed in non-PJS patients, deserve to be mentioned as a 
feature of this disease. 
 
The Peutz-Jeghers polyps are characterized by a stroma with abundant smooth muscle 
forming branching bundles (Rintala 1959) and occur throughout the gastrointestinal tract 
Review of the Literature 
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(stomach, small intestine, colon and rectum), and in some patients also in other locations 
like the nose or gallbladder (Wada et al. 1987; de Leng et al. 2007a) and in single cases 
also the urinary tracts (Sommerhaug and Mason 1970), and bronchi (Sommerhaug and 
Mason 1970). They are benign hamartomatous tumors, and as discussed further below, it 
is unclear whether the gastrointestinal carcinomas originate from polyps or randomly, 
rendering the two as completely distinct entities. Despite this benign nature, the polyps 
cause serious complications to the Peutz-Jeghers patients if left uncontrolled, as they may 
bleed, obstruct or intussuscept the intestine. 
 
Point mutations affecting the LKB1(STK11) gene are known to cause PJS in around 70% 
of cases, and large deletions of the whole LKB1 locus on chromosome 19p13.3 may raise 
the number of cases explained by LKB1 mutations to >90% (Aretz et al. 2005; Hearle et 
al. 2006b; Volikos et al. 2006). Other genes that would cause PJS have not been found, 
despite efforts screening genes such as the homeobox gene CDX2, serine-threonine 
kinase 13 (STK13), Protein-kinase C gamma (PRKC!), the kallikrein-related peptidase 
KLK10, Pleckstrin homology, Sec7 and coiled/coil domains 2 gene (PSCD2), the LKB1-
interacting proteins STK11IP, BRG1, STRAD", and MO25", as well as the polarity-
associated MARK/Par1 gene family (Woodford-Richens et al. 2001; Buchet-Poyau et al. 
2002; Alhopuro et al. 2005; de Leng et al. 2007b). 
 
1.1 Peutz-Jeghers polyposis among the gastrointestinal polyposes 
 
Gastrointestinal polyps can be classified into neoplastic (like adenomatous, serrated and 
carcinoid polyps), hyperplastic (including inflammatory polyps), hamartomatous (e.g. 
Peutz-Jeghers, fundic-gland, juvenile, and Cowden polyps) and mesenchymal 
(gastrointestinal stromal tumors, smooth muscle, neural, lymphoid or vascular tumors) 
types.  
 
Adenomatous polyps in particular have been extensively studied, due to their clinical 
significance being both common and pre-malignant, and a detailed model of the 
morphological and molecular chain of events leading to their formation and progression 
was presented already two decades ago (Fearon and Vogelstein 1990). In this model, a 
cell in the normal epithelium adquires two mutations in the Adenomatous Polyposis Coli 
(APC) gene, turning its progeny epithelium dysplastic. Hypomethylation changes the 
expression patterns in this epithelium turning it into an early adenoma, then K-Ras 
mutations and later SMAD2/DPC4/DCC mutations occur as the adenoma progresses 
becoming an intermediate and then a late adenoma. As p53 mutations occur, the 
adenoma progresses into an in situ carcinoma, which further develops into an invasive 
carcinoma. As SRC gene mutations occur the carcinoma is ready to metastasize.  
 
Review of the Literature 
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Peutz-Jeghers polyps, as well as other more rare polyps, have naturally been analyzed for 
the markers already characterized in adenoma-carcinoma progression, like the loss of 
tumor suppressor functions in the epithelium, and Wnt-signaling deregulation. In PJS 
polyposis aberrant Wnt signaling has been implicated to arise through failure of mutated 
LKB1 to activate Wnt signaling inhibitor GSK-3", and through overexpression of Wnt5a 
(Lai et al. 2011). In immunohistochemical studies, "-catenin dislocation (Chaiyapan et 
al. 2010; Ma et al. 2010) and focal p53 overexpression (Entius et al. 2001) have been 
observed in PJS patient polyps.  
 
However, unlike in the adenomas or, for instance, the hamartomatous polyps of Juvenile 
Polyposis (Woodford-Richens et al. 2000), there is no evidence that the epithelium of 
Peutz-Jeghers polyps would represent a clonal expansion, rather, the Peutz-Jeghers polyp 
epithelium is polyclonal and presents with hyperproliferative but otherwise correctly 
organized and separated epithelial units (de Leng et al. 2007c). Thus, the Peutz-Jeghers 
polyp initiation and progression differs dramatically from the adenoma model, and 
although it does not exclude focal bursts of clonal expansion and adenoma-carcinoma 
progression within the polyp (Gruber et al. 1998), it does not imply that such progression 
would inevitably occur in PJS polyps, or that such clonal expansions would be more 
probable within a polyp than in the mucosa next to it.  
 
2. The LKB1 kinase 
 
LKB1 is a serine-threonine kinase. It reaches its full kinase activity only when in a 
complex with two other proteins, STRAD (LYK5) and Mo25 (CAB39) (Zeqiraj et al. 
2009), which also stabilize the LKB1 protein and keep it in the cytoplasm, where it can 
phosphorylate its substrates (Figure1, (Dorfman and Macara 2008)).  
 
LKB1 also associates with the molecular chaperone heat shock protein 90 (Hsp90) and 
Cdc37, which stabilize LKB1. A balance between chaperone binding and degradation 
was recently suggested to regulate the levels of LKB1 activity in the cell. LKB1 kinase 
activity was found to be transiently stimulated upon dissociation of Hsp90, which 
simultaneously caused recruitment of Hsp/Hsc70 and the ubiquitin ligase CHIP (carboxyl 
terminus of Hsc70-interacting protein) triggering subsequent LKB1 degradation 
(Boudeau et al. 2003a; Gaude et al. 2012). 
 
Review of the Literature 
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Figure 1. Regulation of LKB1 activity. A schematic depiction of the inside of a cell, with the nucleus on 
the right. The known kinase activities of LKB1 take place in the cytoplasm (lower left-hand corner). LKB1 
possesses a nuclear localization signal (NLS, upper right-hand corner). Without its complex binding 
partners Mouse protein 25 (Mo25) and Ste20-related kinase adapter protein (STRAD), LKB1 is almost 
inactive, and the NLS is exposed to importins, which shuttle it into the nucleus (center of picture). The 
STRAD-Mo25-complex binds to LKB1 in a serial order (upper left-hand corner), with Adenosine 
triphosphate (ATP) binding triggering LKB1 binding, and a Trp-Glu –Phe (WEF) motif on STRAD 
triggering Mo25 binding. The main form of STRAD, STRAD!, has two nuclear export signals (NES) 
tagging it (or the whole complex) for shuttle to the cytoplasm by Chromosome region maintenance (CRM) 
protein 1 or Exportin 7(lower right corner). STRAD", on the other hand, does not contain NESs, leaving 
some active LKB1 complexes inside the nucleus. These nuclear LKB1 complexes have no currently known 
function. The schematic is modified from (Dorfman and Macara 2008) with additional data from (Lizcano 
et al. 2004; Jaleel et al. 2005; Zeqiraj et al. 2009a; Zeqiraj et al. 2009b). 
Review of the Literature 
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PJS-causing mutations either affect the LKB1 kinase function directly by disrupting the 
kinase domain, or indirectly by affecting the binding to this complex (Boudeau et al. 
2004). Among the other LKB1 complex proteins, Mo25 is a chaperone regulating several 
different kinase complexes (Boudeau et al. 2003b; Filippi et al. 2011), and STRAD is a 
pseudokinase, which binds ATP, but has no own kinase activity (Baas et al. 2003). 
Mutations in STRAD have been found to cause another inherited disease, the 
polyhydramnios, megalencephaly and symptomatic epilepsy (PMSE) syndrome 
(Puffenberger et al. 2007), through impaired corticogenesis (Orlova et al. 2010). 
 
LKB1 also undergoes several posttranslational modifications (Figure 2) to reach its full 
activity, multiple phosphorylations by different kinases including Protein kinase C# (Xie 
et al. 2009), p90 ribosomal protein S6 kinase (RSK) (Sapkota et al. 2001) and Protein 
kinase A (PKA), as well as prenylation (farnesylation) (Collins et al. 2000). 
 
There are two different splice variants of LKB1, a full length, major form, and a shorter 
version denoted LKB1s, predominantly expressed in testis(Denison et al. 2009; Towler et 
al. 2008). The regulatory complex partners present with two different gene isoforms 
each, STRAD! STRAD", Mo25! and Mo25". STRAD!, the main isoform of STRAD 
has also been described to have 11 different splice variants, of which only STRAD!-1 
and STRAD!-2 are able to form a complex with Mo25 and LKB1(Marignani et al. 
2007).  
Review of the Literature 
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1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
Human M E V V D P Q Q L G M F T E G E L M S V G M D T F I H R I D
Mouse M D V A D P E P L G L F S E G E L M S V G M D T F I H R I D
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
AMPK consensus site
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
Human S T E V I Y Q P R R K R A K L I G K Y L M G D L L G E G S Y  
Mouse S T E V I Y Q P R R K R A K L I G K Y L M G D L L G E G S Y 
31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60
61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
Human G K V K E V L D S E T L C R R A V K I L K K K K L R R I P N
Mouse G K V K E V L D S E T L C R R A V K I L K K K K L R R I P N
61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90
91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
Human G E A N V K K E I Q L L R R L R H K N V I Q L V D V L Y N E
Mouse G E A N V K K E I Q L L R R L R H R N V I Q L V D V L Y N E
91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120
121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
Human E K Q K M Y M V M E Y C V C G M Q E M L D S V P E K R F P V
Mouse E K Q K M Y M V M E Y C V C G M Q E M L D S V P E K R F P V
121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150
151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
Human C Q A H G Y F C Q L I D G L E Y L H S Q G I V H K D I K P G
Mouse C Q A H G Y F R Q L I D G L E Y L H S Q G I V H K D I K P G
151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180
Autophosphorylation
181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
Human N L L L T T G G T l K I S D L G V A E A L H P F A A D D T C
Mouse N L L L T T N G T L K I S D L G V A E A L H P F A V D D T C
181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210
211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
Human R T S Q G S P A F Q P P E I A N G L D T F S G F K V D I W S
Mouse R T S Q G S P A F Q P P E I A N G L D T F S G F K V D I W S
211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240
241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
Human A G V T L Y N I T T G L Y P F E G D N I Y K L F E N I G K G
Mouse A G V T L Y N I T T G L Y P F E G D N I Y K L F E N I G R G
241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270
271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
Human S Y A I P G D C G P P L S D L L K G M L E Y E P A K R F S I
Mouse D F T I P C D C G P P L S D L L R G M L E Y E P A K R F S I
271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300
PKC(zeta) Possible Casein kinase or other proline directed kinase recognition site
301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330
Human R Q I R Q H S W F R K K H P P A E A P V P I P P S P D T K D
Mouse R Q I R Q H S W F R K K H P L A E A L V P I P P S P D T K D
301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330
331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357
Human R W R S M T V V P Y L E D L H G - A D E D E D - - l F D I E
Mouse R W R S M T V V P Y L E D L H G R A E E E E E E D L F D I E
331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360
Triggered by ionizing radiation, probably ATM
358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387
Human D D I I Y T Q D F T V P G Q V P E E E A S H N G Q R R G L P
Mouse D G I I Y T Q D F T V P G Q V L E E E V G Q N G Q S H S L P
361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390
388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414
Human K A V C M N G T E A A Q L S T K S R A E G R - - - A P N P A
Mouse K A V C V N G T E - P Q L S S K V K P E G R P G T A - N P A
391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418
PKA, RSK farnesylation site Non-matching =30/433
415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 7 %
Human R K A C S A S S K I R R L S A C K Q Q  
Mouse R K V C S - S N K I R R L S A C K Q Q Non-identical: 42/433
419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 10 %
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Comparison of human LKB1 and mouse Lkb1. The alignment demonstrates the high 
conservation of LKB1 and Lkb1 with 90% identity (93% similarity). Coloring indicates the 
kinase domain (green), residues important for MO25 binding (purple), STRAD binding (yellow), 
phosphorylation (pink) and prenylation (blue). Kinases implicated in some of the 
phosphorylations are indicated above the alignment. AMPK = Adenosine monophosphate 
activated kinase, ATM= Ataxia Telangiectasia mutated, PKA= Protein kinase A, 
PKC(zeta)=Protein kinase C#, RSK= p90 ribosomal protein S6 kinase. Figure based on a BlastP 
search query, with additional information from (Wera 1999; Collins et al. 2000; Sapkota et al. 
2001; Sapkota et al. 2002; Martin and St Johnston 2003; Shaw et al. 2004a; Xie et al. 2009; 
Zeqiraj et al. 2009). 
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3. LKB1-mediated cellular functions 
 
All known LKB1 substrates are kinases in the Adenosine monophosphate activated 
kinase (AMPK) family (Lizcano et al. 2004; Jaleel et al. 2005). Phosphorylation by 
LKB1 causes activation of the substrates (I), which in turn regulate a wide array of 
cellular processes involving the physical structures, metabolic states as well as the 
external signaling of the cells (Figure 3, and discussed below). LKB1 also associates 
with the transcription activator and ATP-dependent helicase BRG1 without 
phosphorylating it (Marignani et al. 2001), but still increasing the activity of this 
helicase. 
New aspects of this potentially LKB1-regulated signaling network of AMPK and the 
AMPK related kinases keep emerging, with varying conclusions drawn from different 
cell types and different settings. As a general rule, though, we have proposed that, 
independently of tissue type, the net effect of LKB1 signaling is to advance cellular 
differentiation, as this end result has been shown in enterocytes, gastrointestinal secretory 
cells, exocrine and endocrine pancreatic cells, brown adipocytes, myofibroblasts, 
neuronal cells, lymphoid B- and T-cells as well as germinal cells (Udd and Makela 
2011).  
Advancing cellular differentiation is a property of many other tumor suppressors as well, 
like p53 (Lin et al. 2005), the Retinoblastoma protein (Zacksenhaus et al. 1996),  
Neurofibromin-1 (Hegedus et al. 2007), or the Wilms tumor suppressor 1 (Ellisen et al. 
2001).  
 
3.1 Functions of the AMP-activated Kinase  
 
The AMP-activated Kinase (AMPK), consists of three subunits, !, " and $, with the 
kinase domain residing in !. There are several isoform genes for each subunit, (!1, !2, 
"1, "2, $1, $2, $3), and the $2 and $3 genes have splice variants. All unit types can form 
complexes with each other in vitro, but the composition of the complexes present in vivo 
is dependent both on tissue type and intracellular location (Viollet et al. 2009a).  
AMPK, as its name indicates, is activated by a lowered energy potential inside the cell 
reflected in an increase in monophosphorylated adenosines (AMP) which allosterically 
regulate its kinase activity severalfold (Carling et al. 1989). Phosphorylation by LKB1, in 
comparison, activates AMPK several hundredfold (Hawley et al. 2003). Allosteric 
regulation by either AMP or ADP also potentiates phosphorylation mediated activation 
as it prevents dephosphorylation of AMPK, although ADP in itself does not activate 
AMPK (Davies et al. 1995; Xiao et al. 2011). Apart from LKB1, the Ca
2+/
calmodulin-
dependent protein kinase kinase" (CaMKK", important at least in brain) and by TGF"  
Review of the Literature 
 18 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Signaling of AMPK-related kinases. The LKB1 substrates belonging to the AMPK 
family regulate a wide array of cellular processes, positioning LKB1 as a potential regulator of 
these processes. In this map, a selection of pathways and processes regulated by the AMPK 
related kinases are presented, to illustrate the width of the spectrum of validated and potential 
LKB1 functions. When required, the LKB1 substrates are labeled multiply to visualize their 
complex nomenclature. Arrows indicate activation of the respective target, blunt ends indicate 
suppression. Processes peripheral to brackets are affected by all LKB1 substrate kinases within 
the bracket span. For gene product abbreviations explained please see the List of Abbreviations 
above. Adapted from (Katajisto et al. 2008) with additions from (Beghini et al. 2003; Barnes et 
al. 2007; Kowanetz et al. 2008; Alvarado-Kristensson et al. 2009; Bright et al. 2009; Chun et al. 
2009; Ichinoseki-Sekine et al. 2009; Horike et al. 2010; Koh et al. 2010; Lennerz et al. 2010; 
Romito et al. 2010; Hou et al. 2011; Klutho et al. 2011; Sasaki et al. 2011; Vallenius et al. 2011; 
Daley et al. 2012; Eneling et al. 2012a; Eneling et al. 2012b; Liu et al. 2012; Matenia et al. 2012; 
Ohmura et al. 2012; Sasagawa et al. 2012; Tang et al. 2012; Uebi et al. 2012)  
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activated kinase (TAK1, no physiological context described yet), can also phosphorylate 
and activate AMPK (Bright et al. 2009). 
 
AMPK has an important role as a regulator of energy-dependent cell methabolism. Upon 
energy stress, AMPK activation suppresses the mTOR pathway, which is active under 
nutrient rich conditions and enhanced by growth factor signaling (Shackelford and Shaw 
2009) thereby limiting anabolic processes in the cell and ultimately also cell growth. 
AMPK also directly inhibits fatty acid synthesis by phosphorylating ACC1 (Hardie and 
Carling 1997) and increases “recycling” of nutrients through autophagy, by associating 
with and phosphorylating Unc-51-like kinase (ULK1) (Egan et al. 2011). AMPK activity 
also seems necessary for cell polarity and mitotic progression, at least in drosophila (Lee 
et al. 2007) and it has anti-inflammatory properties, demonstrated e.g. by Buler et al. 
(Buler et al. 2011).  
 
Total knockout of AMPK activity through deletion of both genes for kinase subunits 
(!1
"/"
 and !2
"/"
 double knockout animals) is embryonic lethal at ~E10.5. AMPK!1
"/"
 
mice have no metabolic phenotype whereas !2
"/"
 mice do, and thus the latter kinase 
subunit has been more extensively studied. (Viollet et al. 2003; Viollet et al. 2009a). In 
addition, tissue specific transgenic and knockout mice have been produced to examine 
the roles of the different AMPK subunits in metabolically active tissues like the liver, 
where e.g. !1
"/"
 and !2
"/"
 double knockout leads to reduced mitochondrial biogenesis 
(Guigas et al. 2007), and AMPK!2 has been found (both through knockout and 
overexpression studies) to suppress triglyceride release and increase ketone body 
formation(Foretz et al. 2005; Andreelli et al. 2006) or heart, where the glycolytic 
response to ischaemia is impaired e.g. upon overexpression of dominant-negative 
AMPK!2 (AMPK!2-KD)(Russell et al. 2004). 
 
3.2 Functions of the AMPK related kinases  
 
The functions of the other kinases of the AMPK family do overlap to some extent with 
those of AMPK itself, however they are also much more diverse (Figure 3), and whether 
these kinases also can be phosphorylated by CaMKK" or TAK1 is unclear (Bright et al. 
2009). The BRSK/SAD kinases are necessary for neuronal cell polarization and axon 
formation (Barnes et al. 2007), and a short splice variant of SADB seems to have a role 
in the control of centrosome duplication in all cells types, via phosphorylation of #-
tubulin(Alvarado-Kristensson et al. 2009).  
 
The Par-1 family or microtubule associated protein regulating kinases (MARKs) were 
originally characterized as regulators of oocyte and epithelial cell polarity through 
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regulating microtubule stability. The MARKs phosphorylate microtubule-associated 
proteins such as tau (which forms the aggregates seen in Alzheimers disease). 
Mouse studies of MARK2 and MARK3 knockout have rather revealed that these kinases 
compensate for each other during embryogenesis (double knockout being 
embryoniclethal), but cause very disparate, metabolic phenotypes in the adult. Increased 
adiposity, insulin hypersensitivity, and aberrant glucose metabolism for MARK3 
(Lennerz et al. 2010) and increased insulin sensitivity, increased glucose tolerance, and 
resistance to diet-induced obesity for MARK2. (Klutho et al. 2011; Bessone et al. 1999; 
Hurov et al. 2007)  
 
Studies of MARK2 function on a cellular level has revealed more structural/polarity-
related details, such as being required for correct positioning of the basement membrane 
of epithelial surfaces(Daley et al. 2012) or promotion of mitochondrial transport within 
neurons (Matenia et al. 2012). Testis-specific adherens junctions are maintained by 
MARK4, whose disruption leads to detachment of spermatids from the Sertoli cells(Tang 
et al. 2012). Glioma cell proliferation is enhanced by amplification and overexpression of 
MARK4(Beghini et al. 2003) implicating it as a tumorigenic kinase rather than 
possessing a tumor tuppressor function. 
 
The salt inducible kinases (SIK1-3), as the name indicates, are activated by an increased 
Na
+
 concentration and activation of the plasma membrane pumps for sodium ion 
exchange. Among these, SIK1 has been found to actively increase the transport of 
sodium in response to increased Na
+
 concentration and adrenergic stimuli (Eneling et al. 
2012b). In lung alveolar cells, LKB1 has been found to regulate E-cadherin expression 
and the stability of intercellular junctions through SIK1(Eneling et al. 2012a). SIK1 is 
also an inhibitory modulator of the cellular response to TGF", as it causes degradation of 
activated ALK5 recepors(Kowanetz et al. 2008). SIK1 also specifically regulates the 
differentiation of embryonic stem cells into cardiomyocytes. (Romito et al. 2010).  
 
Both SIK1 and SIK2 have been shown to be involved in the regulation of corticotropin-
releasing hormone transcription in the hypothalamus, with SIK2 mediating TORC 
inactivation in basal conditions, and induction of SIK1 limiting activation responses in its 
transcription(Liu et al. 2012). SIK2 specifically suppresses eumelanogenesis, as Agouti 
mice regained a brown hair color when crossed with SIK2-deficient mice (Horike et al. 
2010). These SIK2 knockout mice also had an altered response to cerebral ischaemia, 
with improved neuronal survival(Sasaki et al. 2011). SIK3, on the other hand, has been 
found necessary for chondrocyte hypertrophy during endochondral ossification occurring 
in growing long bones in mice(Sasagawa et al. 2012). SIK3 knockout mice also show 
hypolipidemia, hypoglycemia, and increased insulin sensitivity due to aberrant fatty acid, 
cholesterol and bile acid metabolism in the liver (Uebi et al. 2012). 
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Whereas SIK1 is implicated in p53 dependent cell cycle arrest and senescence (anoikis) 
(Cheng et al. 2009), Nuak1 has been found to mediate LKB1 dependent p53 activation 
and apoptosis, at least in vitro (Hou et al. 2011). NUAK2 activity is increased in skeletal 
muscles upon contraction, and the muscles of NUAK2-heterozygous mice show impaired 
contraction-stimulated glucose transport (Koh et al. 2010). NUAK2 is also important for 
the contractile properties of nonmuscle cells by activating the formaton of stress fibres 
(Vallenius et al. 2011). Surprisingly however, although NUAK2-heterozygous mice 
collect more adipose tissue when sedentary, they are more active than wildtype mice 
when offered a possibility to exercise (Ichinoseki-Sekine et al. 2009). Embryonic double 
mutants of NUAK1 and NUAK2, on the other hand, show neurodevelopmental defects, 
like exencephaly, facial clefting and spina bifida (Ohmura et al. 2012). Sucrose non-
fermenting related kinase 1 (SNRK1), a kinase more distantly related to AMPK, and also 
a member of its own SNRK family, has a role in the migration of angioblasts during 
artery-vein specification, as shown in zebrafish (Chun et al. 2009).  
 
4. From loss of LKB1 signaling to Peutz-Jeghers Symptoms 
 
The insights into the molecular pathways governed by LKB1, have linked PJS with the 
molecular events underlying other hamartoma syndromes (Figure 4), through the mTOR 
pathway (van Veelen et al. 2011) and Hypoxia-inducible factor (HIF)-1! (Brugarolas and 
Kaelin 2004)(Figure 4), which are indirectly suppressed by AMPK activation (Corradetti 
et al. 2004). Whether this pathway is the key to the characteristic symptoms of PJS or 
whether disruption of other LKB1 substrate functions play a role remains under debate. 
Indeed, the PJS polyps have been suggested to arise through mTOR pathway 
dysregulation (Shaw et al. 2004b; Shackelford et al. 2009), but also, potentially through 
defects in epithelial polarity regulating pathways through the MARKs (Par-1) (Baas et al. 
2004; Jansen et al. 2006). The lentigines, on the other hand, have been suggested to arise 
through deficient SIK2-signaling in melanocytes, although this has not been directly 
demonstrated (Horike et al. 2010).  
 
The sets of LKB1 effectors, however, depend both on tissue type and developmental 
stage (Figure 3, as well as mouse models of Lkb1 loss described below and in Tables 1-
3), and LKB1 actually possesses all categories of tumor suppression function (Kinzler 
and Vogelstein 1998). It is both a caretaker enhancing cellular differentiation (as 
discussed above in Chapter 3 and (Udd and Makela 2011)), a gatekeeper, through direct 
control of the cell cycle (Tiainen et al. 2002) and apoptosis (Karuman et al. 2001; Lee et 
al. 2006), and a landscaper, balancing the stromal-epithelial crosstalk (Katajisto et al. 
2008; Tanwar et al. 2012). This suggests, that the mechanisms behind the PJS symptoms 
will turn out more complex, rather than all driven by mTOR pathway activation. 
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Figure 4. Connections between the hamartoma syndromes. A large group of inherited syndromes 
(green) presenting with hamartomatous tumors, cancers and mucocutaneous pigmentation defects link 
together through signaling connections by gene products (purple) implicated in their pathogenesis 
molecularly. Some converge on activation of the Ras signaling pathway, others join in on an activated 
mTOR pathway, and all display activated HIF1-! signaling. Arrows indicate activation of the respective 
target, blunt ends indicate suppression. Pten related Hamartoma syndromes include the Cowden syndrome, 
Bannayan-Riley-Ruvlcaba syndrome, PTEN-related Proteus syndrome and Proteus-like syndrome. 
HLRCC = Hereditary leiomyomatosis and renal cell cancer, HPGL= hereditary paragangliomatosis with 
phaeochromocytomas. TCA-cycle = citric acid cycle. For gene product abbreviations please see the List of 
Abbreviations above. Adapted from (van Veelen et al. 2011), with additions from (Pollard et al. 2005; 
Koivunen et al. 2007; Reig et al. 2011). 
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5. Loss of LKB1 in cancer beyond the Peutz-Jeghers Syndrome 
 
Early studies of LKB1 in sporadic cancers showed little success in finding roles for LKB1 
beyond the Peutz-Jeghers syndrome (Avizienyte et al. 1998; Bignell et al. 1998; 
Avizienyte et al. 1999), with the exception of a 5% occurrence of biallelic inactivating 
mutations of LKB1 seen in pancreatic and biliary adenocarcinomas (Su et al. 1999). A 
breakthrough on this point came when LKB1 inactivation was identified as a frequent 
event in non small-cell lung cancer (Sanchez-Cespedes et al. 2002). This observation was 
followed by similar observations in breast (Shen et al. 2002; Yang et al. 2004) and 
cervical cancer (Wingo et al. 2009). Curiously, in breast cancer, inactivation often occurs 
through methylation of LKB1 rather than through gene alterations (Fenton et al. 2006), 
suggesting also other forms of cancer may need to be revisited to clarify whether LKB1 
function is maintained. 
 
6. Modeling loss of LKB1 function in the mouse 
 
LKB1 is evolutionarily conserved in animal organisms ranging from the Drosophila fruit 
fly and the C. Elegans nematode to primates, but is not found in yeast, plants or bacteria 
(Homologene record). The mouse homolog of LKB1, Lkb1, lies in a syngeneic locus on 
mouse chromosome 10 and is very highly conserved, giving rise to a protein with 90% 
identical and 93% similar amino acids as in human LKB1 (Figure 2). The high 
interspecies similarity has facilitated the study of Peutz-Jeghers syndrome and LKB1 
functions using animal models, especially mouse models. 
 
As would be expected for such a conserved gene, several mouse models have shown 
LKB1 function to be necessary for the survival of the organism. Systemic homozygous 
inactivation of Lkb1 has been shown lethal both during embryogenesis, mainly as the 
vascular system fails to form correctly in the Lkb1 knockout embryos (Ylikorkala et al. 
2001; Jishage et al. 2002), and when induced in adult mice, as the hematopoietic stem 
cells undergo a process of rapid proliferation and subsequent cell death, resulting in loss 
of all blood cell types (Gan et al. 2010; Gurumurthy et al. 2010; Nakada et al. 2010) 
(Table 1). 
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6.1 Heterozygous Lkb1 knockouts 
 
The Lkb1
+/-
 mouse functions as a model of Peutz-Jeghers Syndrome, and gene knockout 
strategies that cause this genotype have been published by altogether five different 
research groups (Bardeesy et al. 2002; Jishage et al. 2002; Miyoshi et al. 2002; Rossi et 
al. 2002) (Wei et al. 2005) (Table 2) and phenotypes observed in at least 4 mouse 
background strains FVB (Contreras et al. 2008) and FVB/N (Shackelford et al. 2009), 
C57Bl/6J (Wei et al. 2005; Robinson et al. 2008), 129/sv (Robinson et al. 2008)), and 
CD1 (Rossi et al. 2002).  
 
Especially for PJS gastrointestinal polyposis, the Lkb1
+/-
 mouse is a very good model, as 
polyps develop in 100% of animals. It has served to first identify the upregulation of 
cyclooxygenase-2 (COX-2) as a feature of PJS polyposis (Rossi et al. 2002), a 
phenomenon later supported by studies from several different groups (De Leng et al. 
2003; McGarrity et al. 2003; Wei et al. 2003; Takeda et al. 2004). The Lkb1
+/-
 mice also 
display some spontaneous cancer development, in liver (Nakau et al. 2002) and 
endometrium (Contreras et al. 2008), but no pigmentation defects corresponding to PJS 
lentigines have been reported.  
 
A hypomorph Lkb1
fl
 – allele, interestingly, does not cause PJS polyp formation, neither 
in heterozygote Lkb1
+/fl
 (Sakamoto et al. 2005) nor in the homozygote Lkb1
fl/fl 
(Sakamoto 
et al. 2005; Huang et al. 2008)(Table 2) mice, although also in these mice, the expression 
of Lkb1 is reduced to its half or below. Upon further reduction of the LKB1 expression, 
however, in simultaneously AhCRe transgenic mice, treated with beta-naphtoflavone, 
polyposis has been induced also in this model, although with a longer delay than in other 
models (Shorning et al. 2012). 
 
6.2 Epithelial Lkb1 knockouts and cancer 
 
More evidently than in the Lkb1
+/-
 model, several mouse models of homozygous Lkb1 
loss present with cancer, when Lkb1 is lost in epithelial tissues such as skin, prostate, 
mammary gland or endometrium (Gurumurthy et al. 2008; Pearson et al. 2008; McCarthy 
et al. 2009; Contreras et al. 2010) (Table 1). This potential for malignant transformation 
in homozygous Lkb1 knockout models goes well with the observation that the wildtype 
Lkb1 allele is retained in mouse polyps (Miyoshi et al. 2002; Rossi et al. 2002)  (no loss 
of heterozygosity, LOH) and in a subset of PJS patient polyps (Entius et al. 2001; Miyaki 
et al. 2000; De Leng et al. 2003; Wang et al. 1999), but not in PJS cancers, where there is 
either LOH of LKB1 (Wang et al. 1999; Entius et al. 2001; Sato et al. 2001; Kim et al. 
2004; Nakanishi et al. 2004), or CpG island methylation of the LKB1 promoter (Esteller 
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et al. 2001) in accordance with the Knudsen two-hit model for tumor 
suppression(Knudson 1971).  
 
On the other hand, also heterozygous deletion of Lkb1 has been shown sufficient to 
induce progression in several multifactor tumor models, like acceleration of lymphomas 
in Pten
+/-
 mice (Huang et al. 2008), a completely new tumor spectrum in p53
-/-
 mice 
(Wei et al. 2005; Ji et al. 2007); metastasizing lung adenocarcinomas, as well as 
progression of PanIN-lesions into pancreatic ductal carcinomas in Kras
G12D 
mice (Wei et 
al. 2005; Ji et al. 2007) (Table 3). 
 
6.2 Stromal Lkb1 knockout and cancer 
A very recent study (Tanwar et al. 2012) showed induction of endometrial cancer upon 
conditional homozygous ablation of Lkb1 in the stromal cells of the female reproductive 
tract using Muellerian inhibiting substance receptor 2 (Misr2)-Cre. In this model, 
endometrial adenocarcinoma formation did not require any epithelial Lkb1 mutation. 
Carcinoma formation was, however, greatly enhanced with simultaneous heterozygous 
deletion of Lkb1 in the epithelial compartment underlining the importance of crosstalk 
between the two compartments. 
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Table 1. Embryonic stage homozygous (hmz) Lkb1 knockouts  
 
Genotype Tissue involved Phenotype  References 
 
Lkb1
-/- 
all tissues lethality around E8.5-9.5, neural tube defects, mesenchymal cell death,            (Ylikorkala et al. 2001; Bardeesy et al. 2002;  
   
vascular and placental abnormalities, MEF:s produce increased VEGF,      Jishage et al. 2002) 
   are resistant to senescence under hypoxia and to transformation by Ha-Ras  
 
Lkb1
lox/lox
;Mox2-Cre all epiblast derived No rescue of the Lkb1
-/-
 phenotype              (Londesborough et al. 2008) 
 
Lkb1
lox/-
;Tie1-Cre hmz in endothelium Survival until E11.5, decreased vascularization and hemorrhages, recruitment      (Londesborough et al. 2008)  
 het in other tissues, of vascular smooth muscle cells impaired, TGF-beta signaling implicated   
 
Lkb1
lox/lox
;Tie2-Cre hmz in endothelium, embryonic lethality            (Ohashi et al. 2010) 
 hematopoietic cells       
 
Lkb1
fl/fl
 hmz Lkb1S knockout 30% embryonic lethal, males infertile as junctions (ectoplasmic specializations)  (Sakamoto et al. 2005; Towler et al. 2008)  
 all tissues total Lkb1 between sertoli cells and spermatids are not dissolved and spermatids brake         (Denison et al. 2010)   
 5-10fold down (hypomorph) due to loss of Lkb1S 
 
Lkb1
fl/fl
;Mck-Cre hmz in skeletal and cardiac Enlarged atria,  smaller ventricles, cardiomyocyte arrangement normal, reduced (Sakamoto et al. 2006; Habets et al. 2009)  
 muscle, others hypomorph  phosphorylation of AMPK!2 and ACC, AMPK!1 unaffected  in cardiomyocytes.  
     Less AMPK activation, less glucose uptake in skeletal muscle, contraction strength (Sakamoto et al. 2005; McGee et al. 2008) 
     and hypertrophic response to prolonged contractions normal 
 
Lkb1
lox/lox
;Mck-Cre skeletal and cardiac muscle  Reduced weight-bearing muscle mass, reduced voluntary running, earlier fatigue and (Thomson et al. 2007a, 2007b) 
   poor recovery. mitochondrial proteins downregulated in different skeletal muscles,   (Koh et al. 2006) 
   also PGC-1 down, more type IIb  and less type IIx fibres, increased glucose tolerance (Brown et al. 2011; Smith et al. 2011) 
   by increased muscle glucose uptake. 
   In females, progressive myopathy in hindlimbs,with  similar features decraesed type II  (Thomson et al. 2010) 
   A/D-fibre and increased type IIB-fibre content, greater fatigue and slower relaxation,  
   mitochondrial content and thickness of subsarcolemmal layer reduced. 
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Genotype Tissue involved Phenotype  References 
Lkb1
lox/lox
;Mck-Cre skeletal and cardiac muscle 
   Heart failure, common in females, heart weight 10% higher, but protein concentration    (Thomson et al. 2007; Thomson et al. 2010) 
   10% lower, increased left ventricular diameter, 10% decreased heart rate, cardiac output (Jessen et al. 2010) 
   40% decreased, 70% decreased upon ischaemia+reperfusion, mTOR pathway implicated 
 
 
Lkb1
lox/lox
;!MHC-Cre cardiac muscle hmz biatrial enlargement, left ventricular hypertrophy, systolic dysfunction, atrial fibrillation (Ikeda et al. 2009) 
    phenotype similar to dn-CREB-TG mice 
 
Lkb1
fl/fl
;POMC-Cre POMC neurons hmz  POMC-cells developed normally, reduced alpha-MSH secretion and reduced central (Claret et al. 2011)  
 others hypomorph melanocortin tone, females displayed loss of insulin suppression of gluconeogenesis  
   in liver and reduced liver glycogen synthesis  
 
Lkb1
fl/fl
;Albumin-Cre  liver hmz no functional bile canaliculi, polarity defect in ductal cells,  lethal due to biliary stasis (Woods et al. 2011) 
 others hypomorph       
 
Lkb1
lox/lox
;Emx-Cre neural progenitors in Thinner cortex, death of postmitotic neurons, agenesis of the corpus callosum,  (Barnes et al. 2007) 
 dorsal telencephalon reduced cortical axons, SAD kinases (BRSK1/2) implicated in axon formation 
 
Lkb1-RNAi
-pCAG-IRES-GFP
,  ventricular zone, lower  Increased distance between centrosome and nucleus, disrupted centrosome forward 
 (Asada et al. 2007; Asada and Sanada 2010) 
in utero electroporation intermediate zone neurons movement, multiple Tau-1-positive neurites, migration arrest within the IZ,  
    cells reaching cortical plate had axon-like neurite in opposite direction to wt.  
   Phenocopied by S9A-GSK3! or dominant negative APC electroporation. 
 
Lkb1
lox/lox
;Rip2-Cre spinal cord, !-cells, some Spinal cord degeneration from 7-8 weeks, primarily in ascending tracts, with  (Sun et al. 2010a) 
 hypothalamic neurons axon demyelinization, disorganized neurofilaments and microtubules 
   Increased !-cell and islet size, aberrant rosettes, enhanced insulin response  (Sun et al. 2010b) 
   decrease in feeding with reduced expression of hypothalamic NPY and POMC  
 
Lkb1
lox/lox
;Pdx1-Cre all pancreas all cell lineages develop, islets smaller and less compact , pancreatic failure                 (Hezel et al. 2008; Morton et al. 2010) 
   death by 2-3mo , 100% develop benign mucinous cystadenomas,  
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Genotype Tissue involved Phenotype  References 
 
Lkb1
lox/lox
;K14-Cre epidermal tissues delayed hair growth, narrower hair shafts, increased erythema, follicular plugging,  (Gurumurthy et al. 2008) 
   corneal hyperkeratinization, squamocellular carcinoma in 15%   
 
 
Lkb1
fl/fl
;Ah-Cre  prostate hmz 100% atypical hyperplasia and bulbourethral gland cysts, 83% prostate   (Pearson et al. 2008) 
 other tissues hypomorph intraepithelial neoplasia, 39% hyperplasia of the urethra, 11% seminal 
   vesicle squamous metaplasia, lethality by 200 days. More nuclear !-catenin,  
   p-Gsk3!, and Wnt signaling, reduction in Pten activation 
 
 
Lkb1
lox/lox
;Sprrf2-Cre muellerian epithelium, invasive endometrial cancer in 100%, leading to death by local invasion,  (Contreras et al. 2010)  
 urothelium  one case of systemic metastases 
 
Lkb1
lox/lox
;Misr2-Cre muellerian stromal cells Oviductal cysts by 18 weeks, endometrial epithelial hyperplasia and endometrial (Tanwar et al. 2012) 
   carcinoma by 24 weeks. Activation of mTOR signaling in the carcinomas. 
 
Lkb1
lox/-
;Misr2-Cre muellerian stromal cells Phenotype same as in Lkb1
lox/lox
;Misr2-Cre, but the endometrial tumors are  (Tanwar et al. 2012) 
 all other tissues het bigger, more aggressive and invasive 
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Table 1. Homozygous Lkb1 knockouts in adult tissue (inducible knockouts) 
Genotype   Tissue involved Phenotype  References 
Lkb1
lox/lox
;Rosa26-CreERT2 all tissues Severe pancytopenia within 1 week,  lethality within 30 days, first days after (Gan et al. 2010; Gurumurthy et al. 2010)  
+ tamoxifen i.p.  ablation hematopoietic stem cells (HSC) proliferate, then die through apoptosis,  
  wt mice reconstituted with Lkb1 KO bonemarrow die within 60 days 
    
Lkb1
lox/lox
;Ubc-CreERT2 all tissues HSC phenotype as Lkb1
lox/lox
;Mx1-Cre below     (Nakada et al. 2010) 
+ tamoxifen i.p. 
 
Lkb1
lox/lox
;Mx1-Cre variable knockout Pancytopenia in 24-35 days, bonemarrow fails to reconstitute wt mice, lethality (Gurumurthy et al. 2010; Nakada et al. 2010) 
+pIpC induction effect, in most tissues within 120 days due to pancytopenia, HSC proliferate more, but die, become 
   aneuploid with supernumerary centrosomes and aberrant mitotic spindles. 
      
Lkb1
lox/lox
;Pdx1-CreERT2   pancreas  Larger !-cells, more insulin in islets, larger insulin output, higher proliferation, (Fu et al. 2009; Granot et al. 2009)  
+ tamoxifen i.p.   rozettes lost polarity,  nuclei and primary cilia displaced, polarity defect partially 
   mimicked by Par1b knockout, hypertrophy reversed by mTOR inactivation  
 
Lkb1
lox/lox 
+ i.v. infection   liver fasting and fed state hyperglycaemia, increased gluconeogenesis due to active PGC1" (Shaw et al. 2005; Miller et al. 2011)  
With Ad-CRE or CMV-Cre  +higher transcription of gluconeogenetic enzymes, adiponectin reverses partially  
     
Lkb1
lox/lox
;BLG-Cre mammary gland GII invasive ductal carcinomas or solid papillary carcinomas within 46-85 weeks,  (McCarthy et al. 2009) 
+2 rounds of pregnancy  histological features similar to PJS breast cancers, luminal type transcriptome. 
 
Lkb1
lox/lox;
TagIn
(SM-CreERT2(ki)
 mesenchymal derivedPJS gastrointestinal polyposis, by 11 months, as Lkb1
lox/+;
TagIn
(SM-CreERT2(ki)
 mice. (Katajisto et al. 2008) 
+ tamoxifen i.p. smooth muscle cells  
 
Lkb1
fl/fl
;Ah-Cre many tissues hmz, at least PJS gastrointestinal polyposis around 270 days after induction, GI epithelium shows    (Shorning et al. 2009;     
+i.p. !-naphthoflavone prostate, liver, gastro- appearance of intermediate cells and increase in angiotensin related signaling molecules, Shorning et al. 2011; 
 intestinal epithelium, especially Ang II and renin, also defective Par-1 signaling implicated          Shorning et al. 2012) 
 others hypomorph  
Lkb1
lox/lox 
lung  No tumor phenotype observed                            (Ji et al. 2007) 
+ AdCre intranasally 
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Table 2. Heterozygous (het) and other incomplete knockouts of Lkb1  
Genotype Tissue involved Phenotype     References 
Lkb1
+/-
 all tissues het PJS gastrointestinal polyposis, polyp COX-2    (Bardeesy et al. 2002; Jishage et al. 2002; Miyoshi et al. 2002) 
   upregulated, Wnt-signaling deregulated,    (Rossi et al. 2002; Takeda et al. 2004) 
   polyp mTOR signaling upregulated    (Lai et al. 2011), (Shaw et al. 2004b) 
   Osteoblastosis and benign osteogenic tumors leading to paralysis (Robinson et al. 2008)      
   well-differentiated endometrial adenocarcinomas in 50% of females(Contreras et al. 2008)     
   Hepatocellular carcinomas in 70% of males     (Nakau et al. 2002)  
 
Lkb1
fl/fl
 all tissues hypomorph 30% embryonic lethal, no polyps, males infertile   (Sakamoto et al. 2005; Huang et al. 2008) 
 5-10 fold downregulation  Reduced activity of AMPK!1, SIK2 and SIK3 in white adipose  (Gormand et al. 2011) 
   (see also complete knockouts)  
 
Lkb1
lox/+;
Mx1-Cre induced most tissues het,  No observed phenotype after 1-2mo    (Gurumurthy et al. 2010) 
with by pIpC by P15 knockout effect variable 
 
Lkb1
fl/+ 
all tissues "50% down males fertile, sperm counts normal    (Denison et al. 2010) 
 Lkb1S het 
 
Lkb1
lox/+;
TagIn
(SM-CreERT2(ki)
 mesenchymal derived  PJS gastrointestinal polyposis, polyp mTOR signaling upregulated(Katajisto et al. 2008)     
+ i.p. tamoxifen smooth muscle het      
 
Lkb1
lox/+;
Lck-Cre maturing thymocytes het 15% less thymocytes than wildtype    (Cao et al. 2010) 
 
Lkb1lox/+;Tie2Tg/+ endothelial cells het,  impaired revascularization after ischaemia and 
 hematopoietic cells het impaired networking of endothelial cells    (Ohashi et al. 2010) 
 
Lkb1
lox/+;
Mck-Cre skeletal and cardiac 25% reduction in Lkb1 expression in muscle, but phenotype normal (Jessen et al. 2010) 
 muscle het      
 
Lkb1
lox/+;
Sprrf2-Cre muellerian epithelium het   one case of benign uterine tumor    (Contreras et al. 2010)  
 urothelium het 
 
Lkb1
lox/+;
Pdx1-Cre all pancreas het (by E8.5) pancreas normal, disease free for 1.5 years    (Hezel et al. 2008; Morton et al. 2010) 
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Table 3. Incomplete Lkb1 knockouts combined with other tumorigenic manipulations 
 
Genotype Tissue involved Phenotype  References 
 
Lkb1
+/-
;p53
+/-
 all tissues Lkb1 het Reduced survival, accelerated polyposis  (Wei et al. 2005; Takeda et al. 2006)  
  
Lkb1
+/-
;p53
-/-
 all tissues Lkb1 het Reduced survival, accelerated polyposis, new tumor spectrum: bladder,  
   small intestinal, lung, mammary adenocarcinomas, stromal ovarian 
   tumors, all tumors rare. LOH of Lkb1 in intestinal tumor (Wei et al. 2005; Takeda et al. 2006)  
 
Lkb1
fl/+
;Pten
+/-
 all tissues !50% down Pten-type polyps and lymphomas accelerated (Huang et al. 2008) 
 (Lkb1) 
 
Lkb1
fl/fl
;Pten
+/-
 all tissues Lkb1 hypomorph 50% embryonic lethality, Pten-type polyps and lymphomas accelerated (Huang et al. 2008) 
 5-10 fold downregulation  
 
Lkb1
lox/+
; Pten
lox/lox
             muellerian duct stroma    no phenotype       (Tanwar et al. 2012) 
Misr2-Cre  
  
 
Lkb1
+/-
;Catnb
lox/+
  all tissues Lkb1 het More frequent and more multifocal hepatocellular carcinomas, (Miyoshi et al. 2009) 
+ i.v. AdCMV-Cre "-Catenin het in liver histologically similar to Lkb1
+/-
 tumors 
 
Lkb1
+/- 
all tissues Lkb1 het Invasive skin and lung cancers in about 50% of mice, LOH of Lkb1 in  (Gurumurthy et al. 2008) 
+ DMBA treatment    skin cancers, Ras-pathway deregulation 
 
Lkb1
+/-
; 
lox-stop-lox
Kras
G12D 
 all tissues Lkb1 het Lung adenocarcinomas, with 30% metastasizing, no LOH of Lkb1  (Ji et al. 2007) 
+ AdCre intrnasally Kras active in lung       
 
Lkb1
+/lox
; 
lox-stop-lox
Kras
G12D 
lung Lkb1 het and Lung adenocarcinomas, with 30% metastasizing, no LOH of Lkb1  (Ji et al. 2007) 
+ AdCre intranasally Kras active       
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Genotype Tissue involved Phenotype  References 
 
Lkb1
+/lox
;Pdx1-Cre; Pancreas Lkb1 het and Increase in Kras-induced PanIn:s, higher grades, more proliferation, also  
lox-stop-lox
Kras
G12D
 Kras active pancreatic ductal adenocarcinomas, no LOH of Lkb1, p53 pathway downregulated (Morton et al. 2010) 
+ AdCre intranasally 
 
Lkb1
+/lox
;Pdx1-Cre;
 lox-stop 
Pancreas Lkb1 het, Kras  phenotype same as Lkb1
+/lox
;Pdx1-Cre;
 lox-stop-lox
Kras
G12D   
(Morton et al. 2010) 
-lox
Kras
G12D
;p53
R172H/+ 
active, also p53 het 
+ AdCre intranasally 
 
Lkb1
+/lox
;Pdx1-Cre;
 lox-stop 
Pancreas Lkb1 het, Kras phenotype same as Lkb1
+/lox
;Pdx1-Cre;
 lox-stop-lox
Kras
G12D   
(Morton et al. 2010) 
-lox
Kras
G12D
;p21
+/- 
active, also p21 het 
+ AdCre intranasally   
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Table 3. Homozygous Lkb1 knockouts combined with other tumorigenic manipulations 
 
Genotype Tissue involved Phenotype  References 
Lkb1
fl/fl
;Pten
lox/lox
;Ah-Cre many tissues both hmzDiffuse bladder epithelium hyperplasia with papillary growths,  (Shorning et al. 2011) 
+i.p. !-naphthoflavone others Lkb1 hypomorph squamous metaplasia and nuclear pleiomorphism, no invasion,  
   mTOR pathway and EMT markers upregulated  
 
Lkb1
lox/lox
;K14-Cre
 
all tissues Lkb1 het squamocellular carcinomas as in DMBA-treated Lkb1
+/-
 mice  (Gurumurthy et al. 2008) 
+ DMBA treatment    but with 100% prevalence 
 
Lkb1
lox/lox
; 
lox-stop-lox
Kras
G12D 
 lung hmz, Kras active Lung tumors with squamous morphology, 60% metastases, upregulation (Ji et al. 2007; Carretero et al. 2010) 
+ AdCre intranasally  of EMT associated genes, Src-family kinases , FAK pathway activation 
 
Lkb1
lox/-
; 
lox-stop-lox
Kras
G12D 
 lung hmz, Kras active Tumor phenotype similar to Lkb1
lox/lox
; 
lox-stop-lox
Kras
G12D
   (Ji et al. 2007)  
+ AdCre intranasally other tissues Lkb1 het 
 
 
Lkb1
lox/lox
; Pten
lox/lox
     muellerian duct stromal cells endometrial carcinomas accelerated (found by 9weeks),  (Tanwar et al. 2012) 
Misr2-Cre oviductal cysts accelerated (found by 12 weeks), vaginal and 
   cervical squamous cell tumors add to tumor spectrum 
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7. Treatments and treatment trials in Peutz-Jeghers syndrome and its 
mouse models 
7.1 Treatments in clinical use 
The currently used treatment of PJS is surgical, with extensive follow-up to detect 
tumors, and removal upon detection of both polyps and cancers according to standard 
guideline protocols for cancer surgery. To illustrate the substantial scope of this regimen, 
the follow-up protocol recommended by the USA National Comprehensive Cancer 
Network (as of 2nd November 2009, http://www.nccn.org/) is listed in Table 4. 
 
Table 4. Recommended follow-up for Peutz-Jeghers patients.  
Examination           Starting age   Frequency           Sex 
Stomach and small intestine endoscopy       10  every 2-3 years          both 
CT enterography/small intestine enteroclysis       10  every 2-3 years          both 
colonoscopy      late teens every 2-3 years          both 
testicular exam, observation for femininization    10  annually           males 
clinical breast exam           25  every 6 months        females 
pelvic exam and pap-smear (+ultrasound exam)   25  annually         females 
pancreas screening by magnetic resonance  
cholangiopancreatography and/or ultrasound         30            every 1-2 years           both 
CA 19-9 blood test            30            every 1-2 years           both 
+ preventive measures against lung cancer as for the general population  both 
 
7.2 Experimental treatments 
In Lkb1
+/-
 mice, the Cyclooxygenase (COX)-2 inhibitor celecoxib suppresses polyposis 
(II), and rapamycin, an mTOR inhibitor, has been found to reduce both polyposis (Wei et 
al. 2008; Robinson et al. 2009; Shackelford et al. 2009; Wei et al. 2009) and endometrial 
cancers (Contreras et al. 2010) (Table 5).  
 
While the molecular basis for assuming mTOR regulation plays a role in polyp formation 
and progression is clear (see e.g. Figure 3), pinpointing a molecular context for COX-2 in 
PJS polyposis is harder. The cyclooxygenases (1 and 2) function as rate-limiting 
enzymes in the prostaglandin synthesis, and COX-2 can be induced by various stimuli, 
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e.g. during inflammation. LKB1 signaling has been shown to directly suppress the 
transcription of COX-2 in lung cancer (Upadhyay et al. 2006; Ratovitski et al. 2010), but 
COX-2 could also be indirectly induced (Pham et al. 2008) in the PJS polyps by a 
dysregulated local renin-angiotensin signaling system (Shorning et al. 2012).  
 
Also in PJS patients, two different experimental medical treatments have been reported, 
of which one study (II) included in this thesis used celecoxib against polyposis (II), and 
the other study used an mTOR inhibitor, everolimus, against polyposis and pancreatic 
cancer (Klumpen et al. 2011). Whereas COX-2 inhibitors are currently not recommended 
for use in PJS, due to their cardiovascular side effects, everolimus is now being evaluated 
in at least one larger clinical trial, providing some positive prospect for the development 
of a future treatment to the PJS patients. 
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Table 5. Treatment trials in Lkb1 mouse models 
Genotype Treatment Outcome  References 
Lkb1
+/- 
Celecoxib Polyposis attenuated, polyp vascularity (MVD) reduced    (II, Udd et al. 2004) 
 COX-2 inhibitor 
 
Lkb1
+/- 
Rapamycin Polyposis attenuated, more efficiently in males, (MVD) reduced  (Wei et al. 2008; Wei et al. 2009;  
 mTOR-inhibitor no effect on hepatocellular carcinoma incidence     Robinson et al. 2009; Shackelford et al.        
         2009) 
Lkb1
lox/lox
;Rosa26-CreERT2  rapamycin No response (Gan et al. 2010; Gurumurthy et al.  
+ tamoxifen i.p.    2010)  
 
Lkb1
lox/lox
;Rosa26-CreERT2 metformin No response (Gan et al. 2010)  
+ tamoxifen i.p. AMPK activator  
    
Lkb1
lox/lox
;Ubc-CreERT2 rapamycin No response     (Nakada et al. 2010) 
+ tamoxifen i.p. 
 
Lkb1
lox/lox
;Mx1-Cre rapamycin No response     (Gurumurthy et al. 2010; Nakada et al.  
        2010) 
+pIpC induction   
 
Lkb1
lox/lox
;Pdx1-CreERT2 rapamycin !-cell hypertrophy reversed, polarity defect not affected   (Fu et al. 2009; Granot et al. 2009)  
+ tamoxifen i.p.    
 
Lkb1
lox/lox
;Sprrf2-Cre rapamycin endometrial cancers regressed to 50%, mTOR signaling normalized, (Contreras et al. 2010)  
   tumors regrew after cessation of treatment 
 
Lkb1
lox/lox
;Misr2-Cre rapamycin suppression of endometrial carcinogenesis, and of oviductal cyst formation (Tanwar et al. 2012) 
 
Lkb1
fl/fl
;Ah-Cre rapamycin No effect on gastrointestinal epithelial phenotype   (Shorning et al. 2009) 
+i.p. !-naphthoflavone 
 
Lkb1
lox/lox
;!MHC-Cre rapamycin  hypertrophy of cardiomyocytes reversed     (Ikeda et al. 2009) 
 
Lkb1
lox/lox
; 
lox-stop-lox
Kras
G12D 
sunitinib survival prolonged from 9.1 to 11.7 weeks, similar incidence of metastases (Gandhi et al. 2009) 
+ AdCre intranasally RTK inhibitor  
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Genotype Treatment  Outcome     References 
 
Lkb1
lox/lox
; 
lox-stop-lox
Kras
G12D
 BAPN,  reduced tumor burden, fewer large tumors and less   (Gao et al. 2010) 
+ AdCre intranasally       LOX inhibitor)  invasion-promoting collagen deposits 
 
Lkb1
lox/lox
; 
lox-stop-lox
Kras
G12D
 dasatinib,  No response     (Carretero et al. 2010) 
+ AdCre intranasally SRC inhibitor 
 
Lkb1
lox/lox
; 
lox-stop-lox
Kras
G12D
 BEZ235, PI3K inhibitor + No response     (Carretero et al. 2010) 
+ AdCre intranasally selumetinib, MEK inhibitor 
 
Lkb1
lox/lox
; 
lox-stop-lox
Kras
G12D
 dasatinib + BEZ235+      Significant tumor regression     (Carretero et al. 2010) 
+ AdCre intranasally         selumetinib 
 
Lkb1
lox/lox
; 
lox-stop-lox
Kras
G12D
 Docetaxel  No response     (Chen et al. 2010) 
+ AdCre intranasally 
 
Lkb1
lox/lox
; 
lox-stop-lox
Kras
G12D 
Docetaxel +  No response     (Chen et al. 2010) 
+ AdCre intranasally        selumetinib 
 
Lkb1
fl/+
;Pten
+/-
 AZD8055   lymphomas regressed to 50%, regrew after cessation   (Garcia-Martinez et al. 2011)  
 
mTOR inhibitor 
 
Lkb1
fl/+
;Pten
+/-
 GDC-0941  lymphomas regressed to 50%, regrew after cessation, 40% regression by(Garcia-Martinez et al. 2011) 
 
PI3K inhibitor  second treatment, second cessation regrowth speed same as first
 
(Wullschleger et al. 2012)  
 
Lkb1
fl/+
;Pten
+/-
 metformin  lymphomas marginally delayed, 100% affected by 1 year  (Huang et al. 2008)  
 AMPK activator 
 
Lkb1
fl/+
;Pten
+/-
 phenformin  lymphomas delayed, 20% disease free by 1 year    (Huang et al. 2008) 
 AMPK activator  
 
Lkb1
fl/+
;Pten
+/-
 A-769662  lymphomas delayed, 10% disease free by 1 year    (Huang et al. 2008) 
 AMPK activator 
 
Lkb1
fl/fl
;Pten
lox/lox
;Ah-Cre rapamycin  Bladder hyperplasia reduced, reduced proliferation,   (Shorning et al. 2011) 
+i.p. !-naphthoflavone  mTOR and EMT markers normalized 
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AIMS OF THE STUDY 
 
The general aim of this thesis project was to gain further insight into the role of the 
LKB1 inactivation in pathogenesis of Peutz-Jeghers Syndrome, hoping both that the 
findings may benefit Peutz-Jeghers Syndrome patients, and that the new knowledge may 
help us to better understand more common cancers and diseases. 
 
Detailed aims of the thesis subprojects: 
 
I  To facilitate the search for LKB1 substrates by establishing cell lines with and 
without LKB1 kinase activity, from primary cells 
 
II  To characterize the effect of heterozygous LKB1 inactivation on the 
differentiation of gastric epithelium in the formation of Peutz-Jeghers syndrome 
polyposis 
  
III  To study the effects of COX-2 inhibition on Peutz-Jeghers polyposis, and to test 
whether COX-2 inhibitors could be used for polyp chemotherapy. 
 
IV  To model the effects of DNA damage in Peutz-Jeghers syndrome by carcinogen 
induction in the Lkb1+/- mouse, and to evaluate the effects of COX-2 inhibition in 
this setting 
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MATERIALS AND METHODS 
1. Materials 
Materials generated for and /or used in the thesis studies are listed below with references, 
and the according original publications are referred to in Roman numerals.  
 
Mouse lines       source/reference    used in 
CD1     Jackson Laboratories   I-IV 
C57BL/6    Jackson Laboratories   II, III, IV 
Lkb1     (Ylikorkala et al. 2001)  I-IV 
Cox-2     (Dinchuk et al. 1995)   II 
 
Cell lines     source/reference    used in 
HeLa/wt LKB1, /kinase dead LKB1   (Sapkota et al. 2002)     I 
Immortal wt and Lkb1-/- MEFs    by author, (Hawley et al. 2003)  I 
  
HEK 293 cells       ATCC     I 
 
Antibodies          source/reference   used in 
anti-BRSK1, -BRSK2, -NUAK1, -NUAK2,   
-QIK, -SIK, -QSK, -MARK1, -MARK4,  
-MELK, -AMPK!1,  and -AMPK!1,!2 (Lizcano et al. 2004)  I 
anti-MARK3 and MARK2 (#05-680) Upstate Biotech             I 
anti-T-loop-phosphorylated AMPK       (Sugden et al. 1999)  I 
anti-Lkb1           (Sapkota et al. 2001)  I 
anti-LKB1          (Boudeau et al. 2003b)  I 
anti-CD31 (#01950D)     PharMingen   II 
anti-COX-2 (#160126)   Cayman Chemical  II 
anti-actin (#AC-40)         Sigma-Aldrich  II 
anti-pepsinogen C (Pg-1)    (Furihata et al. 1973)  III, IV 
anti-intrinsic factor         (Howard et al. 1996)  III 
anti-TFF2 (hSP)    (Elia et al. 1994)  III 
anti-H+/K+-ATPase (HA3-923)  Affinity Bioreagent  III 
anti-Cdx2 (MU392A-U9)   Bio-Genex Laboratories III 
anti-gastrin (#A0568), -lysozyme (#A0099)  
-chromogranin A(#A0430), -Ki-67 (TEC-3) DakoCytomation  III 
anti-desmin (DE-R-11),-Muc6 (NCLMUC-6) Novocastra   III  
anti-SMA (#A5691)          Sigma-Aldrich  III 
Griffonia simplicifolia lectin II (B-1215)    Vector    III 
anti- HA epitope     Roche    I 
anti-GST and -FLAG epitopes     Sigma-Aldrich  I 
Anti-myc antibodies         (Lizcano et al. 2004)  I 
horseradish peroxidase secondary   Pierce    I 
biotinylated secondary antibodies        Vector    II-IV 
FITC anti-mouse IgM    Vector    III 
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AlexaFluor488 secondary antibody   Invitrogen   III 
Antibodies          source/reference   used in 
ARK-kit for antibody biotinylation   DakoCytomation  III 
ApopTag apoptosis detection kit   Chemicon/Serologicals II 
Tyramide Signal Amplification-kit   Perkin Elmer   II 
 
Gene epression arrays   source/reference   used in 
Mg-U74a2 GeneChip   Affymetrix   III 
RNEasy-kit     Qiagen    III 
Superscript II kit   Qiagen    III 
ENZO kit    Enzo Life Sciences  III 
 
DNA Cloning Reagents  source/reference   used in 
Quikchange mutagenesis kit  Stratagene   I 
Mega kit    Qiagen    I 
DYEnamic ET terminator chemistry  Amersham Biosciences I 
pCR2.1-TOPO vector   Invitrogen   I 
pEBG2T vector   (Sanchez et al. 1994)  I 
pGEX6P-1 vector   Amersham   I 
 
Kinase Assay Reagents  source/reference   used in 
P81 phosphocellulose paper  Whatman   I 
P32ATP    Amersham biosciences I 
AMARA peptide    (Dale et al. 1995)  I 
LKBtide peptide   (Lizcano et al. 2004)  I 
Vydac 218TP5215 C18 columns Separations Group  I 
PHOS-select Iron chelate gel  Sigma-Aldrich  I 
 
Other Major Reagents  source/reference   used in 
Phenformin    Sigma-Aldrich  I 
AICA-riboside   Toronto Res. Chemicals, Inc. I 
Celecoxib    Searle-Pharmacia, Pfizer II, IV 
N-methyl-N-nitrosourea  Sigma-Aldrich  IV  
 
2. Methods 
 
All methods used in the thesis are described in detail in the four original publications, 
and are listed alphabetically below with references to the respective original publication 
(Roman numerals). The methods used by the author are described below the list in 
further detail.  
 
Method/Protocol      used in 
Affymetrix expression profiling    III 
Antibody raising and affinity purification   I 
Tissue/cell culture      I 
DNA fragment cloning     I 
Fluorescence microscopy     III 
Gastroscopy       II 
Generation of immortalized MEFs    I 
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Genotyping by PCR      I-IV 
Immunohistochemistry     II-IV 
Method/Protocol      used in 
In vitro kinase assay      I 
Isolation of primary MEFs     I 
Light microscopy      II-IV 
Mouse breeding/crossing     I-IV 
Phosphopeptide sequence analysis    I 
Protein overexpression     I    
RNA extraction      III 
Sequencing       I 
Site-directed mutagenesis     I 
Tissue preparation for histology    II-IV 
Tryptic phosphorylation mapping    I 
TUNEL assay       II 
Western blot analysis      I, II 
Mouse maintenance (I-IV) 
All mice had free access to food and water before and throughout the studies.  Animal 
health was monitored according to the recommendations of the animal welfare 
committee of the University of Helsinki, and ethical permissions for the studies were 
obtained from the State Provincial Office of Southern Finland. The given permit numbers 
were STU48A and STU536A for Lkb1-knockout mouse breeding (I-IV), STU 413A for 
the celecoxib study (II) as well as STU1222A and STU444A for the MNU and celecoxib 
study (IV). Celecoxib powder was mixed at a concentration of 1500 parts per million (II) 
or 150 parts per million (IV) with global rodent chow (Harlan Teklad), and stored at -
20°C until being fed to the mice. N-methyl-N-nitrosourea was diluted freshly into the 
drinking water of the mice, at a concentration of 120ppm and bottles replaced every 48-
72h (IV). Upon weaning of the experimental animals, tail-end or ear-clipping samples 
were incubated with Proteinase K, before samples were genotyped with primers designed 
against the wildtype or knockout allele of Lkb1 (Ylikorkala et al. 2001) (I-IV) or of COX-
2 (Dinchuk et al. 1995) (II). Genotyping of all animals was also performed (I), or 
repeated (II-IV) upon dissection.  
Mouse embryo fibroblast (MEF) culture (I) 
Wildtype and Lkb-/- E9.5 embryos were mechanically fragmented and outgrowing cells 
were cultured for 5 days, in Dulbecco's modified Eagle's Medium supplemented with 
penicillin, streptomycin, glutamine, 10% fetal bovine serum, and 10% conditioned 
medium from wild-type MEFs. After this initial establishment of the cultures, the cells 
were passaged according to a modified 3T3 protocol (Denhardt et al. 1991). 
Tissue analyses (II-IV) 
For histological analysis, mouse tissue samples were dissected and fixed overnight in 2-
4% paraformaldehyde, followed by microdissection and further sample selection under 
an inverted microscope. Samples were then embedded in paraffin and sectioned using 
standard techniques. All immunochemistry was performed on deparaffinized and 
rehydrated sections. When appropriate, endogenous peroxidase was quenched in 3% 
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hydrogen peroxide. Epitope retrieval was achieved either by heat induction with DAKO 
Target Retrieval (DakoCytomation), or by peptic induction with trypsin (Difco 
Laboratories). Some antibodies were used without epitope retrieving pretreatment. 
Immunostainings were counterstained with hematoxylin (Thermo Fisher Scientific) or 
eosin (II-IV). 
 
Microvessel density (MVD) was scored manually during microscopy from sections 
stained for CD31, as described (Seno et al. 2002)(II). Pepsinogen altered pyloric glands 
(PAPG) were also scored manually during microscopy as the ratio of glands negative for 
pepsinogen C staining (III). The mean size of TFF2 expressing cells was scored as the 
cross section area in micrographs of immunostained tissue sections, using ImageJ 
software (http://rsb.info.nih.gov/ij/) (III). Numbers of different cell types per gastric unit 
were scored manually from micrographs of histological sections (III).  
 
For immunoblot analysis, snap frozen tissue was lysed in 1X Laemmli buffer with 
Qbiogene Lysing Matrix D in a FastPrep homogenizer (QBiogene, Carlsbad, CA). 
Western blotting analysis was performed using standard protocols. 
 
  
Patient studies 
 
Permissions for patient studies were obtained from the Finnish National Agency for 
Medicines (now Finnish Medicines Agency, Fimea) and from the ethical board of the 
department of surgery at the University of Helsinki Central Hospital (II). 
Archived paraffin-embedded samples of polyps and biopsies of normal gastric tissue 
from Peutz-Jeghers patients were obtained from the Helsinki University Central Hospital 
Pathology Department (II, III). 
 
Statistical analyses 
Statistical analyses were performed using the SPSS statistical software package (Apache 
Software Foundation, SPSS Inc.) II, III, or the PASW statistics 18.0 package (SPSS Inc.) 
IV. 
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RESULTS AND DISCUSSION 
1. LKB1 phosphorylates and activates kinases of the AMPK family 
 
1.1 LKB1:STRAD:Mo25 phosphorylates and activates 13 AMPK-related kinases in 
vitro (I) 
In a cell-free system, in vitro, BRSK1, BRSK2, NUAK1, NUAK2, SIK, QIK, QSK, 
MARK1, MARK2, MARK3 and MARK4 were shown to phosphorylate AMARA 
peptide, previously known to phosphorylate AMPK (Dale et al. 1995), and this 
phosphorylation was 50-200-fold increased when LKB1:STRAD:Mo25 complex was 
present, but not when LKB1 was in isolation. MELK also phosphorylated AMARA 
peptide, but this activity was not affected by the LKB1:STRAD:Mo25 complex. This in 
vitro data showed that phosphorylation by the LKB1 complex serves to activate the 
AMPK family kinases except MELK. 
T-loop threonines (T) corresponding to the Thr172 in AMPK!1 known to be 
phosphorylated by the LKB1:STRAD:Mo25 complex (Hawley et al. 2003), were 
converted to alanines (A) and to glutamic acids (E). As expected for manipulations of an 
activating phosphorylation site, TA-mutations, preventing phosphorylation, abolished or 
decreased kinase activity, whereas most TE-mutants, partly mimicking phosphorylated 
threonine residues, behaved as constitutively activated kinases. Although TE-mutants of 
MARK1-3, did not show this phenotype, there is no reason to assume the physiological 
role of the site to be different in these kinases. To address the same issue by an 
independent technology, the localization of the LKB1 phosphorylation site on BRSK2 
and NUAK2 was reconfirmed with analysis of 32P-labelled tryptic digests. Taken 
together, these data demonstrated that a specific LKB1 phosphorylation site 
corresponding to the Thr172 in AMPK!1 was conserved on the T-loop of the AMPK 
family kinases. 
 
1.2 LKB1 is required in vivo for activation of AMPK and several AMPK-related 
kinases (I) 
Peptide antibodies against the AMPK-related kinases were generated, and their ability to 
immunoprecipitate (IP) the kinases was tested on lysates of HEK-293 cells, in which the 
respective kinases had been overexpressed. For MARK2/3 a commercial antibody was 
available. IP of NUAK2, QIK, QSK, SIK, MARK1, and MARK4 was performed from 
Lkb1
-/-
, and Lkb1+/+ mouse embryonic fibroblasts (MEFs), and a kinase activity assay 
performed. This experiment revealed a 7-35-fold decrease in the kinase activities of 
NUAK2, QIK, QSK, SIK, MARK1, and MARK4 and a !3fold decrease in MARK2/3 
kinase activity in the LKB1 knockout cells. There was no significant decrease in the 
expression of any of these kinases in the Lkb1-/- MEFs, as shown by immunoblotting.  
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This data indicated that, in vivo, in Lkb1 deficient cells, the activity of the LKB1 
substrates was reduced, due to the absence of activating phosphorylation. 
 
1.3 Phenformin does not activate LKB1 (I) 
 
When treated with phenformin, Lkb1-/- MEFs showed no activation of AMPK!1, 
whereas Lkb1+/+ MEFs showed an upregulation of AMPK!1 activity, as previously 
shown (Hawley et al. 2003). Interestingly, however, none of the activities of the other 
AMPK related kinases was affected in either cell type. This data showed, that although 
AMPK activation by phenformin is dependent on the presence of LKB1, phenformin 
does not cause AMPK activation by activating LKB1. These studies were repeated also 
in normal HeLa cells, which do not express LKB1 (Hawley et al. 2003), and in HeLa 
cells stably expressing wildtype or catalytically inactive LKB1 (Sapkota et al. 2002; 
Hawley et al. 2003) with similar results. 
 
2. Cyclooxygenase-2 Promotes PJS polyposis 
 
2.1 In Lkb1
+/- 
 mice, COX-2 collaborates with LKB1 in driving polyposis (II) 
Cox-2 expression is found in Lkb1+/- mouse polyps (Rossi et al. 2002; Takeda et al. 
2004) and in PJS patient polyps (Wei et al. 2003; McGarrity et al. 2003). We saw a 40-
60% prevalence of COX-2 expression in the polyps, depending on the size of the polyp, 
and a !50% reduced Lkb1+/- mouse gastric polyp burden in Cox-2-/- and Cox-2+/- 
backgrounds. The number of large polyps was reduced more significantly than the 
number of small polyps, suggesting that COX-2 accelerates the growth of polyps rather 
than affecting the initiating steps of polyp formation. 
 
2.2 COX-2 inhibitor treatment reduces PJS-type polyposis (II, IV) 
Lkb1
+/- mice were treated with COX-2 inhibitor celecoxib at 1500ppm (I), or 150ppm 
(IV), and polyp burden decreased !7-fold with the higher dose, and !4-fold with the 
lower dose. Treated Lkb1+/- polyps had a lower microvessel density, also found to 
correlate with COX-2 inhibitor response in the ApcDelta716 model of familial adenomatous 
polyposis (Seno et al. 2002). There were no changes in the morphological appearance of 
the polyps upon treatment, nor any increase in epithelial cell apoptosis.  
 
PJS patient gastric polyposis was assessed by gastroscopy before and after a 6-month 
treatment with 200 mg celecoxib bidaily, corresponding to half the dose used in the 
treatment of familial adenomatous polyposis patients. Digital recordings of the 
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gastroscopies were analyzed by 5 independent evaluators, who graded the severity of the 
polyposis. In two out of six examined patients, significant improvement of the polyposis 
grading score was seen with celecoxib treatment, suggesting beneficial effects of COX-2 
inhibitor treatment in at least a subset of PJS patients. 
 
3. Gastrointestinal epithelial differentiation defects in PJS 
 
3.1 Gastric gland cell differentiation is impaired in Peutz-Jeghers polyps (III, IV) 
 
Gastric polyps from Lkb1+/- mice and PJS patients were studied for epithelial 
differentiation markers, and found to display either weak or no Pepsinogen C antibody 
reactivity (suggesting loss of antral gland, mucopeptic and chief cells). Fundic polyps 
also displayed absence of parietal cells as based on H+/K+-ATPase antibody staining and 
cell morphology. The presence of enteroendocrine cells, on the other hand (as based on 
Chromogranin A stainings) was deemed unaltered. The RNA-expression profiles of 
Lkb1
+/-
 polyps and normal mucosa supported the immunohistochemical findings, with 
downregulation of genes attributed to the expression profiles recorded for chief cells 
(Mills et al. 2003) and parietal cells (Mills et al. 2001).  
 
The glands of the mouse and patient polyps were occupied by Muc-6-expressing 
precursor gland cells. These cells did not fit to the description of “antralizing” or 
spasmolytic peptide expressing metaplasia (Goldenring and Nomura 2006), as there was 
no increase in spasmolytic peptide expression, no increase in the size of the cells 
expressing it, and no colocalizing expression of intrinsic factor.  Also antralization, 
defined as incorrect specification of fundic epithelium into antral epithelium was not 
evident, as gastrin expression was seen widely in antral polyps and antral Lkb1+/- 
mucosa, but not in fundic polyps, nor in fundic Lkb1+/- mucosa. Taken together, this data 
suggested a block in the terminal differentiation process of the glandular cells of the 
gastric Peutz-Jeghers polyps, rather than a metaplastic process of “de-differentiation”. 
 
Gastric epithelial differentiation was also studied in the mucosa of young Lkb1+/- mice, 
prior to the onset of polyposis. In this setting, we also found a statistical difference in the 
occurrence of glands lacking Pepsinogen C expression. Some of these glands also had an 
aberrant pattern of cell proliferation (as shown by staining the Ki-67 epitope), there was, 
however, no stromal aberrations attributed to polyp development detectable at this point, 
suggesting aberrant epithelial differentiation to be the earliest sign of polyp initiation. 
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 3.2 Secretory cell differentiation is impaired in intestinal Peutz-Jeghers polyps (III) 
 
Lysozyme staining was absent from the crypts of small intestinal Lkb1+/- and PJS patient 
polyps suggesting loss of Paneth cells. This was supported also by Cdx-2 staining nuclei 
of the crypt cells, as this intestinal differentiation regulator should be downregulated to 
allow for Paneth cell specification (Blache et al. 2004). Also among normal appearing 
Alcian Blue-staining goblet cells, there were a large number of cells of similar 
morphology that also stained with lysozyme antibody, suggesting the increased presence 
of less differentiated so-called “intermediate” cells (Udd and Makela 2011). These 
findings indicated that apart from gastric gland cells, also intestinal secretory cells show 
impaired differentation in PJS polyposis, and suggested the disruption of a common 
regulatory mechanism for the differentiation of the gastric gland cells and the intestinal 
secretory cells. 
 
4. DNA damage accelerates Lkb1
+/-
 polyposis (IV) 
 
4.1 DNA damage potentiates Lkb1
+/-
 polyp growth without malignant 
transformation (IV) 
 
Lkb1
+/-
 mice were treated with the DNA-alkylating agent N-Methylnitrosourea (MNU), 
causing decreased survival compared to wildtype mice undergoing the same treatment, 
and an almost 10-fold increase in gastric polyp burden compared to untreated Lkb1+/- 
mice. There was no change in polyp morphology upon treatment, and only one case of 
dysplasia was seen in a polyp. The size of the polyps was increased through enhanced 
epithelial proliferation. Polyp numbers, including the number of small polyps, were also 
dramatically increased, suggesting that additional mutations accelerate both the initiation 
and progression of PJS polyposis.  
 
4.2 COX-2 inhibition does not prevent DNA-damage induced polyposis acceleration 
(IV) 
 
Groups of Lkb1+/- and wildtype mice treated with MNU were subsequently also given 
celecoxib. This treatment decreased the mortality of the mice slightly, but not 
significantly. Also the gastric polyp burden was slightly reduced, but the reduction was 
not statistically significant. This suggested that treatment with COX-2 inhibitors might 
not be sufficient to prevent the progress of Peutz-Jeghers polyposis in the presence of 
additional DNA-damage. 
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4.3 Gastric epithelial differentiation defect unaffected by DNA damage 
 
The occurrence of gastric glands lacking pepsinogen C expression is increased upon 
treatment of wildtype animals with carcinogens such as MNU (Yamamoto et al. 1997), 
and pepsinogen C expression can be normalized by COX-2 inhibitor treatment (Hu et al. 
2004). In the Lkb1+/- mice, however, no further increase above the basal was observed 
upon MNU treatment, and no effect was seen with celecoxib, although the wildtype mice 
followed an expected pattern of increase and decrease. These observations suggest, that 
the mechanism underlying lack or loss of pepsinogen C expression is different in the 
Lkb1
+/-
 setting, and rather a sign of nascent polyposis than of carcinogen exposure. 
 
GENERAL DISCUSSION 
 
Before our finding that the AMPK-related kinases are LKB1 substrates (I), the research 
fields of LKB1 biology, and of kinase biology were broadened by two major advances. 
The human kinome, the phylogenetic tree of all human kinases was published (Manning 
et al. 2002), and LKB1 itself was described to phosphorylate AMPK (Hawley et al. 
2003). The sequence similarity of the kinases related to AMPK, then gave reason to 
study the whole family for interaction. Indeed, the link to AMPK itself was already very 
interesting, as it linked PJS to the other hamartoma syndromes (see Figure 4, in the 
Review of the Literature section) and surprisingly enough – to diabetes, in which AMPK 
regulation plays a central role (Viollet et al. 2009b).  
 
Finding the other substrates diversified the view of the capacities of LKB1, fitting the 
optimistic nickname “Master Tumor Suppressor” branded by the author’s namesake 
(Yoo et al. 2002). Through its many substrates, LKB1 is positioned to regulate a 
multitude of cellular processes associated with polarity (asymmetric cell division, 
apicobasal determination of epithelial cells, neuronal axon specification, and directional 
migration of mesenchymal cells) (Jansen et al. 2009) intracellular transport(Asada and 
Sanada 2010), transcription (Katoh et al. 2006), and response to energy stress (van der 
Velden et al. 2011; Jeon et al. 2012). 
 
The prominent role of LKB1 in the regulation of a wide variety of cell responses further 
reinforced interest in studying the molecular mechanisms of tumor formation in PJS. In 
addition, mutations in LKB1 have been found also in some of the most common cancer 
types, such as lung adenocarcinoma (Sanchez-Cespedes et al. 2002) and breast cancer 
(Shen et al. 2002), further highlighthing the central role of LKB1 in tumor biology in 
general. 
Results and Discussion 
48 
 
The finding, that phenformin (an analogue of metformin, the well established drug for 
type II diabetes) did not function as an activator of LKB1 (I) diminished some of the 
enthusiasm for finding potential anti-cancer use for this kind of pharmacological agents, 
biguanides. A theoretical basis for antineoplastic function still remains however, with the 
confirmed link to AMPK and mTOR pathway regulation. Data from epidemiological 
studies have given variable results, some of which support a protective effect from long-
term metformin treatment while others do not. Some anticancer effects of metformin 
have been demonstrated in vitro, and the subject remains a prime research topic (Pollak 
2012). 
 
Apart from the studying LKB1, and loss of LKB1 function on a cellular level, we also 
studied it on a tissue level, as we explored the differentiation of epithelial cells in the 
polyposis-prone gastrointestinal mucosa of Lkb1+/- mice and Peutz-Jeghers patients (III). 
We found that the differentiation into more specialized glandular cells was impaired in 
the stomach both in the pre-polypotic young mucosa, and more dramatically in the 
polyps. This finding was unexpected based on the previously accepted paradigm, that the 
Peutz-Jeghers epithelium is well differentiated, and contains all epithelial cell types and 
lineages native to the site of occurrence(Estrada and Spjut 1983; Tobi 1999). Since then, 
more evidence for pre-polypotic changes in epithelial stability due to LKB1 
heterozygosity have been reported by Langeveld et al., who have shown that unaffected 
PJS patient intestinal epithelium has a more diverse pattern of genetic methylation than 
that of controls, and that the mucosal regeneration process in the crypts is protracted 
(Langeveld et al. 2012). 
 
Although mesenchymal derived cells have been shown capable of driving Peutz-Jeghers 
polyp formation (Katajisto et al. 2008), these findings suggested a role also for the 
epithelial compartment in Peutz-Jeghers polyp formation. Either it could influence 
polyposis by providing an alternative pathway to polyp formation, as suggested by the 
findings of pre-polyposis foci of poor differentiation (III), aberrant methylation patterns 
and prolonged clonal cell expansion (Langeveld et al. 2012) in the epithelium prior to 
stromal aberrations. On the other hand, it could also function as a partner for epithelial-
stromal interaction as suggested by the observation that polyposis is much more 
pronounced, upon concomitant loss of Lkb1 in the epithelial compartment (Katajisto et 
al. 2008).  
 
Reduced TGF! signaling activity has been shown in the stromal smooth muscle lineage 
cells (Katajisto et al. 2008), and in Lkb1 deficient fibroblasts (Vaahtomeri et al. 2008), 
and may be involved in the signaling from stroma to epithelium, whereas the candidates 
for aberrant epithelial to stromal are less conspicuous. Perhaps this route of signaling is 
influenced by the Notch pathway, an important pathway in cell-cell communication and 
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cellular differentiation, which is affected when Lkb1 is homozygously deleted in 
gastrointestinal epithelium (Shorning et al. 2009).  
 
We also observed defects in the differentiation of secretory cells in intestinal polyps, 
suggesting the blockade of a common mechanism in the differentiation of these cell 
types. Such common denominators are the Notch signaling, which promotes proliferation 
and inhibits secretory cell differentiation both in the intestine and in the stomach (Kim 
and Shivdasani 2011; Kim and Shivdasani 2011), and the Notch-regulated transcription 
factor SAM pointed domain ETS factor (Spdef), which is driving the differentiation of 
secretory cells in both the stomach and the intestine (Gregorieff et al. 2009; Horst et al. 
2010; Noah et al. 2010), and also preferentially driving the differentiation of goblet cells 
from goblet/Paneth cell precursors (Noah et al. 2010). Intestinal secretory cells also 
depend on the transcription factor Math1 (Yang et al. 2001), and Notch signaling also 
represses this transcription factor (Kim and Shivdasani 2011). However, Math1 is not 
expressed in the stomach (Yang et al. 2001); therefore, inhibition of Math1 is an unlikely 
cause for loss of secretory cell fate in this compartment. 
 
We also explored the role in PJS polyposis of COX-2, an enzyme eminently attributed to 
control of the inflammatory reaction (Vane et al. 1994)(II, IV). Many aspects of the 
inflammatory reaction are beneficial to tumor cell growth, and cells associated with 
inflammation, like immune cells and myofibroblasts, as well as inflammation related 
signaling molecules, cytokines, are commonly present also in tumor stroma (Mantovani 
et al. 2008). Such an activated stroma has been shown to carry the potential to induce 
malignant transformation in epithelial cells (e.g. (Hayward et al. 2001)). Also, polypoid 
structures in the mucous membranes can be caused by inflammation, for instance during 
Helicobacter pylori infection as inflammation –associated hyperplastic polyps occur in 
the stomach and regress upon eradication of the bacteria (Ohkusa et al. 1998). Although 
these structures, per se, are unrelated to the genetically determined polyps of the Peutz-
Jeghers syndrome, this highlights the potency of inflammatory signaling mediators in 
tumor and polyp formation. 
 
In other gastrointestinal polyposes, and particularly in Familial Adenomatous Polyposis 
(FAP), the effects of COX-2 have been extensively studied, and COX-2 has been shown 
to correlate with increased adenoma size (Azumaya et al. 2002), higher proliferation 
(Sato et al. 2003) and a worse prognosis of colorectal adenomas and cancers (Han et al. 
2010). COX-2 inhibition has also consistently been found to reduce the adenoma burden 
in both FAP patients(Steinbach et al. 2000), and in the ApcMin/+ mouse model of the 
disease (Jacoby et al. 2000) through inhibition of angiogenesis and upregulation of 
apoptosis (Leahy et al. 2002). 
 
In Peutz-Jeghers polyposis there is a dispute regarding where COX-2 is expressed, some 
results show epithelial expression (Rossi et al. 2002; De Leng et al. 2003), others 
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generalized stromal expression (Takeda et al. 2004). This could be due to a difference 
between patient (Rossi et al. 2002; De Leng et al. 2003) and mouse polyps (Takeda et al. 
2004). Also a third, unexplored but potential source of COX-2 expression could be 
activated stromal immune cells, especially macrophages as shown in the ApcMin/+ mice 
(Nakanishi et al. 2011). From the perspective of tumor progression, however, this 
ambiguity makes very little difference, as COX-2 could excert its effects on polyp 
progression as well from any of these locations, as demonstrated in Juvenile Polyposis 
(Brazowski et al. 2005).  
 
Here, in studies II and IV, we did not dwell further on the localization of COX-2 
expression, but rather studied the effects of ablation or inhibition of COX-2 on polyposis. 
We found COX-2 to promote the growth of polyps, rather than their initiation (II), which 
is consistent with observations from Familial Adenomatous Polyposis, where COX-2 is 
linked to later stages of polyp growth (Takeda et al. 2003). COX-2 inhibition by 
celecoxib did not increase the apoptosis frequency in the PJS polyp epithelium, and 
polyp numbers were not altered as much as the polyp burden in the Lkb1+/- mice, 
whereas in FAP, a reduction in polyp number was associated with an increase in the 
apoptotic ratio of adenomas in a subset of patients (Sinicrope et al. 2004). However, we 
found that COX-2 inhibition reduced the microvessel density, as a sign of reduced 
angiogenesis, which may limit the flow of nutrients to the polyp cells.  Therefore, 
celecoxib treatment could potentially have caused the suppression of Lkb1+/- polyposis 
through decreased epithelial proliferation, as observed upon celecoxib treatment in FAP 
(Sinicrope et al. 2004). Such an effect could have been mediated both through the 
restriction of angiogenesis, as direct inhibition, or both. In study IV, in addition, COX-2 
inhibition was not particularly effective in limiting the Lkb1+/- polyp growth, when 
initiation had been spurred by mutagenesis affecting also other genes than Lkb1 (IV), 
suggesting this kind of growth increase was independent of COX-2 and dependent on 
some other factors.  
 
It remains a subject for further study which genes can drive Peutz-Jeghers polyp 
initiation and progression in the LKB1-heterozygous mucosa, although focal 
accumulation of mutated p53 in a carcinogen treated Lkb1+/- polyp (IV) supported the 
notion that p53 is one of them (Wei et al. 2005; Takeda et al. 2006). Interestingly, the 
additional mutations acquired by the Lkb1+/- epithelium in this study did not cause 
significant amounts of malignant transformation in the polyps, conforming to a 
previously rather debated finding, that LKB1 loss drives benign growth but resistance to 
malignant transformation (Bardeesy et al. 2002).  
 
This phenomenon of transformation resistance upon loss of LKB1 has recently has been 
suggested to depend on impaired AMPK regulation of nicotinamide adenine dinucleotide 
phosphate (NADPH) homeostasis, disrupting the redox balance of cells growing under 
energy stress conditions typical for malignant growth (Jeon et al. 2012), so that toxic 
reactive oxygen species accumulate and eventually destroy the cell. Such a chain of 
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events has also been suggested to occur in hematopoietic stem cells upon Lkb1 ablation 
(Gan et al. 2010; Gurumurthy et al. 2010; Nakada et al. 2010). In all other settings, 
however, where this intriguing effect has been observed, the cells have suffered a 
homozygous deletion of LKB1, whereas in the PJS polyps, both the epithelial and the 
stromal cells are heterozygous for LKB1 loss. As it is not evident that a similar reactive 
oxygen species overload can arise also when some LKB1 function is retained, it remains 
unclear whether this mechanism protects against polyp transformation or not. 
 
As a follow-up on the findings in studies III and IV and on other studies on the different 
roles of the stroma and epithelium in polyp formation in Peutz-Jeghers polyp formation 
(Katajisto et al. 2008; Shorning et al. 2009), further studies on the topic of epithelial-
stromal interaction in the formation of polyps would be of future interest. Using mouse 
models, as in the studies presented here, such experimentation could be performed as 
sequential induction of Lkb1 loss in the stroma and epithelium, by means of inducible 
Cre transgenes.  
 
The TagIn-Cre mouse (Katajisto et al. 2008) is a good model for temporally controlled 
stromal Lkb1 inactivation, but a similar model of gastric epithelial Lkb1 knockout 
remains to be developed. The Lgr5Cre-ERT2(Barker et al. 2007) could be used to study 
specifically the antral mucosa (Barker et al. 2010) or alternatively, intestinal PJS 
polyposis could be studied instead in this system or with the villinCre-ERT2 (el Marjou et al. 
2004). The main reason for studying gastric polyps in the Lkb1+/- mouse model, has been 
the high frequency of polyps in the stomach (100% of mice) as compared to the intestine 
(5-10% of mice depending on background, our unpublished data). On the other hand, 
stydying intestinal polyposis would make sense from the point of view of Peutz-Jeghers 
patient symptoms, as intestinal polyps cause the bulk of polyp-related complications 
 
The recent finding that stromal loss of LKB1 can evoke endometrial carcinogenesis 
without manipulations of the epithelial compartment (Tanwar et al. 2012) also suggests 
that there is a need for the development of similar compartmentally regulated stromal vs. 
epithelial model systems for the study of other tissues subject to LKB1-regulated 
tumorigenesis (like the mammary gland (Shen et al. 2002) or lung (Sanchez-Cespedes et 
al. 2002)).  
 
Considering the vast amount of LKB1 substrates and interactors that also could be 
explored in this manner, large-scale experimentation through some less time-consuming 
approach than the mouse models, perhaps systematic organoid culture combined with 
bioinformatical processing of data, could be applied as a starting point for clarifying the 
tissue and cell type specific functions of LKB1 in Peutz-Jeghers polyposis and beyond. 
 
Conclusions 
52 
SUMMARY AND CONCLUSIONS 
In conclusion, evaluating the impact of the findings of this thesis upon the research field, 
Study I has turned out highly relevant for the further studies of LKB1 signaling both in 
vitro and in vivo. This study, together with a previous report on AMPK activation by 
LKB1 (Hawley et al. 2003), and other research groups arriving at similar findings (Shaw 
et al. 2004) opened up whole new fields for research, as described above. Also the MEF 
cell lines engineered for study I have been used by other research groups to clarify 
specific cellular functions of AMPK and LKB1 (see e.g. (Sakamoto et al. 2004; Rattan et 
al. 2005; Memmott et al. 2008)). 
 
In the case of study II, however, right after the publication of the study, concern was 
raised regarding the cardiovascular side-effects of COX-2 selective inhibitors, and 
closely related drug, rofecoxib, was withdrawn from the market, and thus no further 
clinical trials with celecoxib were pursued. The advancement of the findings from study 
II into any form of clinical practice would require more large scale clinical assessment of 
COX-2 inhibitor efficacy in the treatment of the disease before coming into question. As 
of yet, there has been no apparent interest in such studies from the side of the drug 
manufacturers, and currently mTOR inhibitors are the primary line of PJS treatment 
research being pursued in the clinics.  
 
The cardiovascular side effects of coxibs have, however, since then proven to be of the 
same level as for most non-selective non-steroidal anti-inflammatory drugs 
(www.mhra.gov.uk/home/groups/plp/ documents/websiteresources/con068576.pdf), and 
the future of COX-2 inhibitor therapy in PJS is still not determined. Treatment with 
COX-2 inhibitors is accepted as standard protocol for patients suffering from Familial 
Adenomatous polyposis (Phillips et al. 2002). Also in other forms of cancer, the efficacy 
of COX-2 inhibitors, primarily celecoxib, have been widely addressed. There are, for 
example, phase II trials in head-and neck cancer (Mohammadianpanah et al. 2012), 
ovarian cancer (Reyners et al. 2012) and breast cancer (Young et al. 2012) that recently 
have been reported successful. Insomuch that at the time being, COX-2 inhibition is seen 
as a significant tool in fighting cancer in general (McCarty 2011). Thus, a new stance to 
COX-2 inhibitor treatment in PJS may well be taken in the future. The treatment could, 
potentially, be offered in combination with other medical and surgical treatments, rather 
than on its own. 
 
The findings of study III, in turn, may increase our future understanding of glandular 
cancer development in Peutz-Jeghers disease and perhaps also beyond. Kato et. al  (Kato 
et al. 2011) recently reported widespread pseudo-pyloric metaplasia in a PJS patient, 
calling for re-evaluation of previously studied polyp and tumor series from PJS patients 
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for this type of lesions, and suggesting similar LKB1-linked deregulation of glandular 
cell differentiation also outside the stomach. 
 
In study IV, as we treated Lkb1+/- mice with the MNU carcinogen to achieve additional 
DNA damage, we did not observe any substantial neoplastic response in the Lkb1+/- 
polyps, supporting the notion that LKB1 loss drives benign growth but resistance to 
malignant transformation (Bardeesy et al. 2002). On the other hand, the initiation of 
Peutz-Jeghers polyps was dramatically increased. Study IV thus suggests LKB1 
heterozygosity may cooperate with mutations in other tumor suppressors and oncogenes 
in the formation of Peutz-Jeghers polyps, rather than this process being purely LKB1-
dependent.  
 
In the future, characterization of the functions of each of the separate LKB1 substrates 
will be required to grasp the system of LKB1 regulated signaling circuits. Considering 
also the vast amount of other potential interacting partners in LKB1 signaling and the 
combinations of LKB1 loss with mutations in other genes as well as the roles of these 
substrates and interactors in different tissues, the characterization of LKB1 signaling has 
only begun. This research field will continue to require the combined efforts of research 
groups, on a large scale, to reach understanding of the Peutz-Jeghers syndrome and of 
LKB1 function. 
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